Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Killer Cells, Natural | 13 | 2023 | 2201 | 1.750 |
Why?
|
Immunotherapy, Adoptive | 4 | 2020 | 1469 | 0.750 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2019 | 23 | 0.670 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2019 | 84 | 0.660 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2021 | 212 | 0.660 |
Why?
|
Interleukin-15 | 4 | 2023 | 185 | 0.480 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1896 | 0.390 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 1802 | 0.380 |
Why?
|
Myeloid Progenitor Cells | 1 | 2010 | 113 | 0.350 |
Why?
|
Receptors, Immunologic | 2 | 2006 | 1410 | 0.300 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2019 | 3615 | 0.260 |
Why?
|
Cell Differentiation | 5 | 2019 | 11530 | 0.230 |
Why?
|
Receptors, KIR3DL1 | 2 | 2019 | 26 | 0.220 |
Why?
|
Flow Cytometry | 4 | 2022 | 5870 | 0.210 |
Why?
|
Adrenoleukodystrophy | 1 | 2024 | 143 | 0.200 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2023 | 1374 | 0.200 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5821 | 0.200 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2021 | 91 | 0.190 |
Why?
|
Lentivirus | 1 | 2024 | 508 | 0.190 |
Why?
|
Immunophenotyping | 3 | 2022 | 1869 | 0.180 |
Why?
|
Toxoplasmosis | 1 | 2021 | 94 | 0.180 |
Why?
|
Leukemia | 1 | 2008 | 1522 | 0.170 |
Why?
|
Ki-67 Antigen | 1 | 2002 | 629 | 0.170 |
Why?
|
Toxoplasma | 1 | 2021 | 157 | 0.170 |
Why?
|
Immunoblastic Lymphadenopathy | 2 | 2017 | 40 | 0.170 |
Why?
|
Receptors, KIR2DL2 | 1 | 2019 | 6 | 0.170 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2021 | 4369 | 0.160 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 1551 | 0.160 |
Why?
|
HLA-C Antigens | 1 | 2019 | 140 | 0.160 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2020 | 1405 | 0.160 |
Why?
|
HLA-B Antigens | 1 | 2019 | 317 | 0.150 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 269 | 0.140 |
Why?
|
HLA Antigens | 3 | 2009 | 1328 | 0.140 |
Why?
|
Lymphoid Tissue | 1 | 2018 | 445 | 0.140 |
Why?
|
Central Nervous System Viral Diseases | 1 | 2016 | 40 | 0.140 |
Why?
|
Antigens, CD19 | 2 | 2020 | 424 | 0.130 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2017 | 125 | 0.120 |
Why?
|
Immunotherapy | 2 | 2023 | 4652 | 0.120 |
Why?
|
Genetic Vectors | 1 | 2024 | 3396 | 0.120 |
Why?
|
Stromal Cells | 3 | 2010 | 1330 | 0.120 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2016 | 234 | 0.120 |
Why?
|
Lymphoma, Follicular | 1 | 2019 | 457 | 0.120 |
Why?
|
Diphtheria Toxin | 1 | 2015 | 253 | 0.110 |
Why?
|
Myelodysplastic Syndromes | 2 | 2024 | 1394 | 0.110 |
Why?
|
Hematopoietic Stem Cells | 1 | 2006 | 3397 | 0.110 |
Why?
|
Bone Marrow | 3 | 2021 | 2911 | 0.110 |
Why?
|
Lymphoma, T-Cell | 1 | 2016 | 304 | 0.110 |
Why?
|
Bone Marrow Cells | 1 | 2020 | 2417 | 0.100 |
Why?
|
Coculture Techniques | 3 | 2020 | 1341 | 0.100 |
Why?
|
K562 Cells | 2 | 2010 | 642 | 0.100 |
Why?
|
Herpesvirus 4, Human | 1 | 2016 | 1078 | 0.090 |
Why?
|
Receptors, KIR | 2 | 2019 | 110 | 0.090 |
Why?
|
Antigens, CD | 3 | 2019 | 4001 | 0.090 |
Why?
|
Monocytes | 1 | 2020 | 2570 | 0.090 |
Why?
|
Colony-Forming Units Assay | 1 | 2010 | 352 | 0.090 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2016 | 612 | 0.090 |
Why?
|
Lymph Nodes | 1 | 2022 | 3465 | 0.090 |
Why?
|
Immunohistochemistry | 3 | 2022 | 11076 | 0.080 |
Why?
|
Mesenchymal Stem Cells | 1 | 2020 | 1642 | 0.080 |
Why?
|
Natural Cytotoxicity Triggering Receptor 3 | 1 | 2008 | 14 | 0.080 |
Why?
|
Leukemia, Experimental | 1 | 2009 | 225 | 0.080 |
Why?
|
Humans | 28 | 2024 | 761596 | 0.080 |
Why?
|
Graft vs Host Reaction | 1 | 2008 | 102 | 0.080 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2008 | 321 | 0.080 |
Why?
|
Antigens, CD34 | 1 | 2010 | 658 | 0.080 |
Why?
|
Central Nervous System Neoplasms | 1 | 2016 | 916 | 0.080 |
Why?
|
Self Tolerance | 1 | 2008 | 123 | 0.070 |
Why?
|
Histocompatibility Testing | 1 | 2009 | 712 | 0.070 |
Why?
|
Antibodies | 1 | 2015 | 2418 | 0.070 |
Why?
|
Cell Count | 1 | 2010 | 1835 | 0.070 |
Why?
|
Organ Transplantation | 1 | 2016 | 1157 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2917 | 0.070 |
Why?
|
B-Lymphocytes | 2 | 2016 | 4758 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4878 | 0.070 |
Why?
|
Lymphocyte Subsets | 1 | 2007 | 309 | 0.070 |
Why?
|
Adoptive Transfer | 1 | 2008 | 819 | 0.060 |
Why?
|
Vaccination | 1 | 2018 | 3384 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 4580 | 0.060 |
Why?
|
Major Histocompatibility Complex | 1 | 2008 | 870 | 0.060 |
Why?
|
Natural Killer T-Cells | 1 | 2008 | 322 | 0.060 |
Why?
|
Fetal Blood | 2 | 2009 | 1347 | 0.060 |
Why?
|
Cyclosporine | 1 | 2007 | 778 | 0.060 |
Why?
|
Receptors, IgG | 1 | 2007 | 559 | 0.060 |
Why?
|
Young Adult | 6 | 2022 | 59260 | 0.060 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2015 | 1640 | 0.060 |
Why?
|
Antigens, Differentiation | 1 | 2006 | 909 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2009 | 4807 | 0.050 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1349 | 0.050 |
Why?
|
Adolescent | 6 | 2024 | 88326 | 0.050 |
Why?
|
Receptors, KIR2DL1 | 1 | 2002 | 13 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5672 | 0.050 |
Why?
|
Hydrocortisone | 1 | 2010 | 1819 | 0.050 |
Why?
|
Disease Progression | 1 | 2019 | 13510 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2024 | 39106 | 0.050 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 2002 | 509 | 0.050 |
Why?
|
Embryonic Stem Cells | 1 | 2009 | 1263 | 0.050 |
Why?
|
Up-Regulation | 1 | 2010 | 4125 | 0.050 |
Why?
|
Niacinamide | 1 | 2023 | 413 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2010 | 18966 | 0.040 |
Why?
|
Aged | 8 | 2021 | 169310 | 0.040 |
Why?
|
Middle Aged | 9 | 2022 | 220921 | 0.040 |
Why?
|
Graft vs Host Disease | 2 | 2009 | 3029 | 0.040 |
Why?
|
Child, Preschool | 2 | 2021 | 42232 | 0.040 |
Why?
|
Child | 4 | 2024 | 80158 | 0.040 |
Why?
|
Adult | 9 | 2022 | 221210 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2022 | 80647 | 0.040 |
Why?
|
Yellow Fever Vaccine | 1 | 2018 | 37 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2008 | 4243 | 0.040 |
Why?
|
Clonal Anergy | 1 | 2018 | 169 | 0.040 |
Why?
|
Male | 10 | 2024 | 360846 | 0.040 |
Why?
|
Female | 10 | 2024 | 392705 | 0.040 |
Why?
|
HIV Seronegativity | 1 | 2018 | 211 | 0.040 |
Why?
|
Biopsy | 2 | 2021 | 6766 | 0.040 |
Why?
|
Chemokine CXCL13 | 1 | 2017 | 59 | 0.030 |
Why?
|
HIV Infections | 2 | 2020 | 17354 | 0.030 |
Why?
|
Eye Proteins | 1 | 2020 | 633 | 0.030 |
Why?
|
Minnesota | 1 | 2016 | 338 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2002 | 1889 | 0.030 |
Why?
|
Splenomegaly | 1 | 2016 | 189 | 0.030 |
Why?
|
Ligands | 1 | 2002 | 3272 | 0.030 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 168 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2020 | 1134 | 0.030 |
Why?
|
Immunotoxins | 1 | 2015 | 175 | 0.030 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2015 | 99 | 0.030 |
Why?
|
Neuropeptides | 1 | 2020 | 944 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2007 | 4176 | 0.030 |
Why?
|
Gene Silencing | 1 | 2020 | 1509 | 0.030 |
Why?
|
Uganda | 1 | 2018 | 1332 | 0.030 |
Why?
|
Lymphocyte Activation | 2 | 2018 | 5485 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2018 | 726 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 2016 | 1900 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2015 | 883 | 0.030 |
Why?
|
Cell Line | 1 | 2006 | 15601 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2016 | 10194 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2020 | 1964 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2020 | 2139 | 0.020 |
Why?
|
Mice | 4 | 2023 | 81539 | 0.020 |
Why?
|
Microvessels | 1 | 2016 | 577 | 0.020 |
Why?
|
Mutation | 1 | 2016 | 30053 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2020 | 2547 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 988 | 0.020 |
Why?
|
Fibrosis | 1 | 2018 | 2049 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2008 | 11904 | 0.020 |
Why?
|
Animals | 5 | 2023 | 168475 | 0.020 |
Why?
|
Collagen | 1 | 2018 | 2638 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2872 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2018 | 2302 | 0.020 |
Why?
|
Gene Frequency | 1 | 2016 | 3606 | 0.020 |
Why?
|
Cytokines | 2 | 2018 | 7396 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3639 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2018 | 1943 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2020 | 58984 | 0.020 |
Why?
|
RNA, Viral | 1 | 2016 | 2846 | 0.020 |
Why?
|
Cell Degranulation | 1 | 2008 | 277 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4111 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8527 | 0.020 |
Why?
|
DNA | 1 | 2021 | 7213 | 0.020 |
Why?
|
Graft vs Leukemia Effect | 1 | 2007 | 121 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2018 | 3156 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8466 | 0.020 |
Why?
|
Monomeric GTP-Binding Proteins | 1 | 2007 | 200 | 0.020 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2007 | 436 | 0.020 |
Why?
|
GPI-Linked Proteins | 1 | 2007 | 470 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5799 | 0.020 |
Why?
|
NFATC Transcription Factors | 1 | 2007 | 389 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2009 | 1827 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2019 | 11120 | 0.010 |
Why?
|
Genotype | 1 | 2019 | 12990 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12463 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5305 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9420 | 0.010 |
Why?
|
Mice, SCID | 1 | 2009 | 2626 | 0.010 |
Why?
|
Models, Biological | 1 | 2020 | 9469 | 0.010 |
Why?
|
Cell Separation | 1 | 2008 | 1720 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10766 | 0.010 |
Why?
|
Calcium Signaling | 1 | 2007 | 733 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2020 | 22176 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15266 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2008 | 3162 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2007 | 2910 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16592 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17904 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2009 | 4317 | 0.010 |
Why?
|
Apoptosis | 1 | 2008 | 9490 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 2009 | 4251 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2019 | 64685 | 0.010 |
Why?
|
Prospective Studies | 1 | 2017 | 54423 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2008 | 16990 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2007 | 10451 | 0.010 |
Why?
|
United States | 1 | 2017 | 72340 | 0.000 |
Why?
|
Time Factors | 1 | 2007 | 39969 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 2009 | 13381 | 0.000 |
Why?
|
Risk Factors | 1 | 2009 | 74213 | 0.000 |
Why?
|